Story perspectives

New Biomarkers Could Delay Alzheimer's by Up to 6 Years

9/11/2025

Summary

Story summary

New studies indicate that drugs targeting the TSPO protein could delay Alzheimer's progression by five to six years before symptoms arise.
Researchers observed that TSPO levels increase with brain inflammation, detectable prior to cognitive decline.
SLIT2 protein levels in eye fluid and blood may serve as early indicators of cognitive decline, correlating with cognitive test scores.
A UC San Diego study identified blood biomarkers linked to self-reported cognitive decline in Hispanic and Latino adults.
Higher nerve injury and inflammation markers correlate with cognitive decline, highlighting the need for accessible early detection methods.

1 of 1

Story summary

New studies indicate that drugs targeting the TSPO protein could delay Alzheimer's progression by five to six years before symptoms arise.
Researchers observed that TSPO levels increase with brain inflammation, detectable prior to cognitive decline.
SLIT2 protein levels in eye fluid and blood may serve as early indicators of cognitive decline, correlating with cognitive test scores.
A UC San Diego study identified blood biomarkers linked to self-reported cognitive decline in Hispanic and Latino adults.
Higher nerve injury and inflammation markers correlate with cognitive decline, highlighting the need for accessible early detection methods.